サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：がん診断の世界市場の評価：製品タイプ別、技術別、がんタイプ別、エンドユーザー別、地域別、機会、予測（2016年～2030年）
市場調査レポート
商品コード
1394581

がん診断の世界市場の評価：製品タイプ別、技術別、がんタイプ別、エンドユーザー別、地域別、機会、予測（2016年～2030年）

Cancer Diagnostics Market Assessment, By Product, By Technology, By Cancer Type, By End-user, By Region, Opportunities and Forecast, 2016-2030F
出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 206 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.65円
がん診断の世界市場の評価：製品タイプ別、技術別、がんタイプ別、エンドユーザー別、地域別、機会、予測（2016年～2030年）
出版日: 2023年12月13日
発行: Market Xcel - Markets and Data
ページ情報: 英文 206 Pages
納期: 3～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のがん診断の市場規模は、2022年の1,475億米ドルから2030年に2,386億6,000万米ドルに達し、2023年～2030年の予測期間にCAGRで6.2%の成長が見込まれています。世界のがん患者数の増加により、市場は飛躍的な成長が見込まれています。がん罹患率の急増は、遺伝的変異、アルコールやタバコの摂取、ホルモンやライフスタイルの変化、発がん性微生物感染、公害の増加などに起因すると考えられ、これらはがん診断市場の促進において重要な役割を果たしています。診断センターの増加も、世界のがん診断市場の促進要因です。これは、よりよい転帰につながるがん検診の増加を促進します。AIや機械学習のような技術をがんの診断や予測に取り入れることが、がん診断市場の成長を促進しています。さらに、産業提携の拡大、革新的な先進の製品の発売、がん検診を後押しする政府の取り組みが、予測期間に市場成長を促進する見込みです。しかし、がん診断処置に伴う高いコストや、がん検診を実施する熟練した専門家の不足が、市場成長の妨げになる可能性があります。

2023年7月、診断情報サービスのパイオニアであるQuest Diagnosticsは、Envision Sciencesとの提携により、同社の下位専門領域の病理企業であるAmeriPathを通じて新しい前立腺がんバイオマーカー検査の導入を発表しました。この新しい組織ベースの検査サービスの目的は、男性の前立腺がんの攻撃的な症例とそうでない症例を区別できる診断に対する緊急の臨床需要への対応の支援です。バイオマーカー検査における最先端の開発は、がん診断市場を牽引する重要な役割を果たすと予測されています。

がん患者の増加

がんは、先進国でも途上国でも例外なく、世界中で主な死因の1つです。近年、がんの主な原因である生活習慣、タバコやアルコールの摂取、放射線被曝の顕著な変化が見られています。これらの要因により、がん患者は急激に増加しています。がんを効果的に治療できる早期の発見に向けた診断の進歩が、がん診断市場の需要を高めています。がん検診は、関連する死亡率を減少させるために、このシナリオでは非常に重要であり、世界のがん診断市場の成長をさらに後押ししています。

世界保健機関（WHO）によると、2020年に新たにがんと診断された患者数は1,929万2,789人で、2025年までに12.1%の成長率で2,161万8,445人に増加すると予測されています。2020年末、過去5年間に乳がんと診断された女性人口は780万人に達し、世界でもっとも罹患率の高いがんとなっています。

診断センター数の増加

がん患者数が日々増加する中、がん検診の需要も増加しており、発展途上国の公共医療施設で利用できる画像診断技術には限りがあるため、数多くの民間診断センターが支店を拡大しています。民間の診断施設に加え、政府出資の診断研究所もがん検診を促進するために設立されています。市場参入企業は既存の組織と協力し、がん診断施設の設立や改修を行っています。また、さまざまな診断企業がさまざまな地域で事業を拡大しています。したがって、診断センターの増加が市場の成長を促進すると予測されます。

例えば、2023年3月には、Cleveland Clinicの最新鋭のがん施設であるFatima bint Mubarak CenterがCleveland Clinic Abu Dhabiにオープンしました。アラブ首長国連邦と中東において、この新しいがん病院は、がんの診断と治療に包括的かつ画期的なアプローチを提供します。新しい診療所のおかげで、患者は必要不可欠なケアと治療を受けるために海外に飛ぶ必要がなくなります。Fatima bint Mubarak Centerは、診断施設、点滴薬を投与する24の個室、集学的がん診察に向けた32の診察室を備えています。

当レポートでは、世界のがん診断市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 世界のがん診断市場に対するCOVID-19の影響

第4章 エグゼクティブサマリー

第5章 世界のがん診断市場の見通し（2016年～2030年）

  • 市場規模と予測
    • 金額
    • 数量
  • 製品別
    • 消耗品
    • 器具
    • サービス
  • 技術別
    • 体外診断検査
    • 画像診断
    • 生検技術
    • その他
  • がんタイプ別
    • 乳がん
    • 肺がん
    • 大腸がん
    • 黒色腫
    • 血液がん
    • 前立腺がん
    • 卵巣がん
    • 胃がん
    • 肝臓がん
    • その他のがん
  • エンドユーザー別
    • 病院
    • 診断研究所
    • 画像診断センター
    • がん研究機関
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 市場シェア：企業別（2022年）

第6章 世界のがん診断市場の見通し（2016年～2030年）

  • 北米
    • 製品別
    • 技術別
    • がんタイプ別
    • エンドユーザー別
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • ロシア
    • オランダ
    • スペイン
    • トルコ
    • ポーランド
  • 南米
    • ブラジル
    • アルゼンチン
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • オーストラリア
    • ベトナム
    • 韓国
    • インドネシア
    • フィリピン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ

第7章 市場マッピング（2022年）

  • 製品別
  • 技術別
  • がんタイプ別
  • エンドユーザー別
  • 地域別

第8章 マクロ環境と産業構造

  • 需給分析
  • 輸出入の分析 - 数量と金額
  • サプライ/バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第9章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第10章 規制の枠組みとイノベーション

  • 臨床試験
  • 特許の情勢
  • 規制当局の承認
  • イノベーション/最新技術

第11章 主要企業情勢

  • マーケットリーダー上位5社の競合マトリクス
  • マーケットリーダー上位5社の市場収益分析（2022年）
  • 合併と買収/合弁事業（該当する場合）
  • SWOT分析（市場参入企業5社）
  • 特許分析（該当する場合）

第12章 価格分析

第13章 ケーススタディ

第14章 主要企業の見通し

  • Abbott
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • QIAGEN
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • Quest Diagnostics Incorporated
  • Merck KGaA
  • Hologic, Inc.
  • Becton, Dickinson and Company

第15章 戦略的推奨事項

第16章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 2. Global Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 3. Global Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 4. Global Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 5. Global Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 6. Global Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 7. Global Cancer Diagnostics Market Share, By Region, In USD Billion, 2016-2030F
  • Figure 8. North America Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 9. North America Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 10. North America Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 11. North America Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 12. North America Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 13. North America Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 14. North America Cancer Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 15. United States Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 16. United States Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 17. United States Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 18. United States Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 19. United States Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 20. United States Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 21. Canada Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 22. Canada Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 23. Canada Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 24. Canada Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 25. Canada Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 26. Canada Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 27. Mexico Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 28. Mexico Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 29. Mexico Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 30. Mexico Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 31. Mexico Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 32. Mexico Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 33. Europe Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 34. Europe Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 35. Europe Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 36. Europe Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 37. Europe Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 38. Europe Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 39. Europe Cancer Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 40. Germany Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 41. Germany Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 42. Germany Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 43. Germany Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 44. Germany Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 45. Germany Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 46. France Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 47. France Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 48. France Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 49. France Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 50. France Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 51. France Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 52. Italy Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 53. Italy Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 54. Italy Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 55. Italy Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 56. Italy Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 57. Italy Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 58. United Kingdom Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 59. United Kingdom Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 60. United Kingdom Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 61. United Kingdom Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 62. United Kingdom Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 63. United Kingdom Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 64. Russia Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 65. Russia Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 66. Russia Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 67. Russia Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 68. Russia Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 69. Russia Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 70. Netherlands Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 71. Netherlands Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 72. Netherlands Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 73. Netherlands Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 74. Netherlands Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 75. Netherlands Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 76. Spain Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 77. Spain Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 78. Spain Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 79. Spain Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 80. Spain Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 81. Spain Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 82. Turkey Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 83. Turkey Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 84. Turkey Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 85. Turkey Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 86. Turkey Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 87. Turkey Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 88. Poland Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 89. Poland Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 90. Poland Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 91. Poland Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 92. Poland Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 93. Poland Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 94. South America Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 95. South America Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 96. South America Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 97. South America Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 98. South America Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 99. South America Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 100. South America Cancer Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 101. Brazil Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 102. Brazil Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 103. Brazil Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 104. Brazil Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 105. Brazil Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 106. Brazil Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 107. Argentina Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 108. Argentina Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 109. Argentina Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 110. Argentina Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 111. Argentina Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 112. Argentina Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 113. Asia-Pacific Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 114. Asia-Pacific Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 115. Asia-Pacific Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 116. Asia-Pacific Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 117. Asia-Pacific Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 118. Asia-Pacific Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 119. Asia-Pacific Cancer Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 120. India Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 121. India Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 122. India Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 123. India Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 124. India Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 125. India Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 126. China Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 127. China Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 128. China Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 129. China Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 130. China Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 131. China Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 132. Japan Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 133. Japan Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 134. Japan Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 135. Japan Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 136. Japan Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 137. Japan Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 138. Australia Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 139. Australia Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 140. Australia Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 141. Australia Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 142. Australia Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 143. Australia Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 144. Vietnam Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 145. Vietnam Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 146. Vietnam Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 147. Vietnam Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 148. Vietnam Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 149. Vietnam Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 150. South Korea Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 151. South Korea Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 152. South Korea Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 153. South Korea Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 154. South Korea Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 155. South Korea Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 156. Indonesia Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 157. Indonesia Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 158. Indonesia Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 159. Indonesia Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 160. Indonesia Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 161. Indonesia Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 162. Philippines Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 163. Philippines Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 164. Philippines Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 165. Philippines Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 166. Philippines Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 167. Philippines Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 168. Middle East & Africa Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 169. Middle East & Africa Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 170. Middle East & Africa Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 171. Middle East & Africa Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 172. Middle East & Africa Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 173. Middle East & Africa Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 174. Middle East & Africa Cancer Diagnostics Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 175. Saudi Arabia Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 176. Saudi Arabia Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 177. Saudi Arabia Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 178. Saudi Arabia Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 179. Saudi Arabia Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 180. Saudi Arabia Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 181. UAE Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 182. UAE Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 183. UAE Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 184. UAE Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 185. UAE Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 186. UAE Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 187. South Africa Cancer Diagnostics Market, By Value, In USD Billion, 2016-2030F
  • Figure 188. South Africa Cancer Diagnostics Market, By Volume, In Million Units, 2016-2030F
  • Figure 189. South Africa Cancer Diagnostics Market Share, By Product, In USD Billion, 2016-2030F
  • Figure 190. South Africa Cancer Diagnostics Market Share, By Technology, In USD Billion, 2016-2030F
  • Figure 191. South Africa Cancer Diagnostics Market Share, By Cancer Type, In USD Billion, 2016-2030F
  • Figure 192. South Africa Cancer Diagnostics Market Share, By End-user, In USD Billion, 2016-2030F
  • Figure 193. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 194. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 195. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022
目次
Product Code: MX10732

The Global cancer diagnostics market size was valued at USD 147.5 billion in 2022 and is expected to reach USD 238.66 billion in 2030 with a CAGR of 6.2% for the forecast period between 2023 and 2030F. As per WHO, cancer is the second leading cause of death around the world. Healthcare professionals and market players are focused on developing more advanced solutions for early cancer diagnosis to reduce the cancer burden. Cancer screening is performed through several techniques depending on the site and type of cancer. The global cancer diagnostics market is expected to grow exponentially due to the increasing number of cancer cases around the world. The surge in the prevalence of cancer can be attributed to inherited mutations, alcohol and tobacco consumption, hormonal and lifestyle changes, carcinogenic microbial infections, and increasing pollution, which play an important role in driving the cancer diagnostics market. Growth in the number of diagnostic centers is also a driving force for the global cancer diagnostics market. It promotes a high number of cancer screenings leading to better outcomes. The inclusion of technologies like artificial intelligence, and machine learning, for the diagnosis and prediction of cancer is driving the growth in the cancer diagnostics market. Additionally, growing industry collaborations, innovative and advanced product launches, and government initiatives to boost cancer screening are anticipated to drive market growth during the forecast period. However, the high costs associated with cancer diagnostic procedures and lack of skilled professionals to perform cancer screenings may hinder market growth.

In July 2023, the pioneer in diagnostic information services, Quest Diagnostics, announced the introduction of a new prostate cancer biomarker test via its subspecialty pathology company, AmeriPath, in association with Envision Sciences. The goal of the new tissue-based test service is to assist in meeting the urgent clinical demand for diagnostics that can distinguish between aggressive and less aggressive cases of prostate cancer in men. Cutting-edge developments in biomarker tests are expected to play a significant role in driving the cancer diagnostics market.

Increasing Number of Cancer Patients

Cancer is one of the leading causes of death globally, without any exception in developed or developing countries. In recent years, a notable change in lifestyle, tobacco and alcohol consumption, and radiation exposure, has been observed which are the leading causes of cancer. Due to these factors, the number of cancer cases has increased drastically. Diagnostic advancement for early detection when cancer can be effectively treated increases the demand in the cancer diagnostics market. Cancer screening becomes crucial in this scenario to reduce associated mortality, further boosting the growth of the global cancer diagnostics market.

As per the World Health Organization, there were 19,292,789 newly diagnosed cancer cases in 2020 which is expected to increase to 21,618,445 with a growth rate of 12.1% by 2025. By 2020-year end, there were 7.8 million women alive who were diagnosed with breast cancer in the past five years, making it the world's most prevalent cancer.

Growth in the Number of Diagnostic Centers

As the number of cancer cases is increasing day by day, the demand for cancer screening is also increasing, and due to limited imaging techniques available at public healthcare facilities in developing countries, numerous private diagnostic centers are expanding their branches. Besides private diagnostic establishments, government-funded diagnostic laboratories are also being established to facilitate cancer screening. The market players collaborate with existing organizations to establish or revamp cancer diagnostic facilities. Various diagnostic companies are also expanding their businesses across different geographies. Thus, growth in the number of diagnostic centers is expected to drive growth in the market.

For instance, in March 2023, The Fatima bint Mubarak Center, a brand-new, cutting-edge cancer facility from Cleveland Clinic, opened at Cleveland Clinic Abu Dhabi. In the United Arab Emirates and the Middle East, the new cancer hospital offers a comprehensive and revolutionary approach to cancer diagnosis and treatment. Patients won't have to fly overseas to receive the essential care and treatment, thanks to the new clinic. The Fatima bint Mubarak Center features diagnostic facilities, 24 private infusion rooms for intravenous medicine administration, and 32 exam rooms for multidisciplinary cancer consultations.

Government Initiatives

Cancer diagnostics research and development of screening tests and products is quite an extensive process that requires a lot of funding. The funding for cancer screening research mainly comes from market players as well as government authorities. In the global cancer diagnostics market, government organizations, associations, and agencies actively promote cancer screening and treatments by providing research funds and driving awareness initiatives, thereby fostering market growth. Additionally, government policies supporting the manufacturing and distribution of cancer diagnostic products are also driving growth in the global cancer diagnostics market.

For instance, according to a press release from The White House, in March 2023, the United States government invested 394.5 million USD in National Comprehensive Cancer Control Program, which includes the Cancer Genomics Program, the National Breast and Cervical Cancer Early Detection Programs to improve various cancer screening and diagnostic services for uninsured and underinsured American women, and the Colorectal Cancer Control Program to increase colorectal cancer screening rates among people age 45 to 75.

In January 2023, the United Kingdom government announced a 10-million-euro investment to develop 29 new breast cancer screening units, these units will be dedicated to reducing the breast cancer burden of the UK. Such government support initiatives and funding for breast cancer research, diagnosis, and treatment are anticipated to drive market growth for the global cancer diagnostics market.

Technological Advancements

The rapid growth of this sector can be attributed to the strong inclination of physicians towards in-vitro diagnostics products for cancer diagnosis. Significant progress has been made in the global market for cancer diagnostics, revolutionizing the detection and treatment of cancer. Advancements in liquid biopsies, next-generation sequencing technology, and molecular diagnostics have enhanced individualized therapy methods and early detection. Targeted medicines, improved patient outcomes, and fewer side effects have been made possible by biomarker identification and accompanied diagnostic testing. Furthermore, the utilization of artificial intelligence and machine learning algorithms has proven to be crucial in analyzing intricate data, enabling more precise diagnosis, and forecasting of treatment outcomes. Ongoing developments in oncology within the field of in vitro diagnostics are revolutionizing cancer care and providing fresh hope in the fight against cancer. Additionally, the segment's expansion is projected to gain momentum due to the growing number of breast cancer patients worldwide.

For instance, in November 2022, Google Health announced a financial agreement with iCAD (a leading market player focused on cancer detection and medical technology development). Through this partnership, iCAD can incorporate Google Health's mammography AI research model in its products for clinical usage. This advancement will help in better and more precise diagnosis of breast cancers.

Impact of COVID-19

Different aspects of healthcare were affected by COVID-19. The global market for cancer diagnostics experienced a notable decline as a result of government-imposed lockdowns and preventive measures across the globe. The market witnessed a reduction in cancer screening.

In addition, several elective examinations, operations, and treatments were canceled or postponed because of preventive restrictions for COVID-19. A report that was published in SAGE in June 2022 states that there was a 44% drop in screening mammography for breast cancer between 2019 and 2020. Despite the COVID-19 pandemic's effects, telehealth initiatives and the application of AI and machine learning gave rise to opportunities for several digital businesses to produce cutting-edge solutions for early cancer detection and prediction. Thus, the overall COVID-19 pandemic negatively affected the screening and treatment rate of cancer but also contributed to technological advancements.

Key Players Landscape and Outlook

Market players have employed a range of strategies to increase the range of solutions they offer and give the customers access to a wide range of innovative and cutting-edge products. Additionally, companies are expanding the range of diagnostic services they offer to capture a bigger portion of the market. Many major industry players are using both different growth techniques, like partnerships, mergers and acquisitions; and the development and launch of new products, to strengthen their position in the global market.

In June 2022, Roche announced the release of its newest cutting-edge tissue staining platform, the BenchMark ULTRA PLUS system, for doctors to decide on a patient's course of therapy in a timely manner, the system provides rapid and accurate test results. Several innovations are included in the new system, including an integrated touchscreen for an enhanced user experience, new intuitive software, remote monitoring capabilities, and more environmentally friendly product packaging and waste management.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on the Global Cancer Diagnostics Market

4. Executive Summary

5. Global Cancer Diagnostics Market Outlook, 2016-2030F

  • 5.1 Market Size & Forecast
    • 5.1.1 By Value
    • 5.1.2 By Volume
  • 5.2 By Product
    • 5.2.1 Consumables
      • 5.2.1.1 Antibodies
      • 5.2.1.2 Kits and Reagents
      • 5.2.1.3 Probes
      • 5.2.1.4 Other Consumables
    • 5.2.2 Instruments
      • 5.2.2.1 Pathology-based Instruments
      • 5.2.2.1.1 Slide Staining Systems
      • 5.2.2.1.2 Tissue Processing Systems
      • 5.2.2.1.3 Cell Processors
      • 5.2.2.1.4 PCR Instruments
      • 5.2.2.1.5 NGS Instruments
      • 5.2.2.1.6 Microarrays
      • 5.2.2.1.7 Other Pathology-based Instruments
      • 5.2.2.2 Imaging Instruments
      • 5.2.2.2.1 CT Instruments
      • 5.2.2.2.2 Ultrasound Instruments
      • 5.2.2.2.3 MRI Instruments
      • 5.2.2.2.4 PET Scan Instruments
      • 5.2.2.2.5 Mammography Instruments
      • 5.2.2.2.6 Other Nuclear Imaging Instruments
      • 5.2.2.3 Biopsy Instruments
      • 5.2.2.4 Other Instruments
    • 5.2.3 Services
  • 5.3 By Technology
    • 5.3.1 In-vitro Diagnostic Testing
      • 5.3.1.1 Polymerase Chain Reaction (PCR)
      • 5.3.1.2 Blood Test
      • 5.3.1.3 In-situ Hybridization (ISH)
      • 5.3.1.4 Immunohistochemistry
      • 5.3.1.5 Next-generation Sequencing (NGS)
      • 5.3.1.6 Microarrays
      • 5.3.1.7 Flow Cytometry
      • 5.3.1.8 Immunoassays
      • 5.3.1.9 Other In-vitro Diagnostic Testing Technologies
    • 5.3.2 Imaging
      • 5.3.2.1 Magnetic Resonance Imaging (MRI)
      • 5.3.2.2 Computed Tomography (CT)
      • 5.3.2.3 Positron Emission Tomography (PET)
      • 5.3.2.4 Mammography
      • 5.3.2.5 Ultrasound
    • 5.3.3 Biopsy Technologies
    • 5.3.4 Other
  • 5.4 By Cancer Type
    • 5.4.1 Breast Cancer
    • 5.4.2 Lung Cancer
    • 5.4.3 Colorectal Cancer
    • 5.4.4 Melanoma
    • 5.4.5 Blood Cancer
    • 5.4.6 Prostate Cancer
    • 5.4.7 Ovarian Cancer
    • 5.4.8 Stomach Cancer
    • 5.4.9 Liver Cancer
    • 5.4.10 Other Cancer
  • 5.5 By End-user
    • 5.5.1 Hospitals
    • 5.5.2 Diagnostic Laboratories
    • 5.5.3 Diagnostic Imaging Centers
    • 5.5.4 Cancer Research Institutes
    • 5.5.5 Others
  • 5.6 By Region
    • 5.6.1 North America
    • 5.6.2 Europe
    • 5.6.3 Asia Pacific
    • 5.6.4 South America
    • 5.6.5 Middle East & Africa
  • 5.7 By Company Market Share (%), 2022

6. Global Ventilator Market Outlook, 2016-2030F

  • 6.1. North America
    • 6.1.1. By Product
      • 6.1.1.1. Consumables
      • 6.1.1.1.1. Antibodies
      • 6.1.1.1.2. Kits and Reagents
      • 6.1.1.1.3. Probes
      • 6.1.1.1.4. Other Consumables
      • 6.1.1.2. Instruments
      • 6.1.1.2.1. Pathology-based Instruments
      • 6.1.1.2.1.1. Slide Staining Systems
      • 6.1.1.2.1.2. Tissue Processing Systems
      • 6.1.1.2.1.3. Cell Processors
      • 6.1.1.2.1.4. PCR Instruments
      • 6.1.1.2.1.5. NGS Instruments
      • 6.1.1.2.1.6. Microarrays
      • 6.1.1.2.1.7. Other Pathology-based Instruments
      • 6.1.1.2.2. Imaging Instruments
      • 6.1.1.2.2.1. CT Instruments
      • 6.1.1.2.2.2. Ultrasound Instruments
      • 6.1.1.2.2.3. MRI Instruments
      • 6.1.1.2.2.4. PET Scan Instruments
      • 6.1.1.2.2.5. Mammography Instruments
      • 6.1.1.2.2.6. Other Nuclear Imaging Instruments
      • 6.1.1.2.3. Biopsy Instruments
      • 6.1.1.2.4. Other Instruments
      • 6.1.1.3. Services
    • 6.1.2. By Technology
      • 6.1.2.1. In-vitro Diagnostic Testing
      • 6.1.2.1.1. Polymerase Chain Reaction (PCR)
      • 6.1.2.1.2. Blood Test
      • 6.1.2.1.3. In-situ Hybridization (ISH)
      • 6.1.2.1.4. Immunohistochemistry
      • 6.1.2.1.5. Next-generation Sequencing (NGS)
      • 6.1.2.1.6. Microarrays
      • 6.1.2.1.7. Flow Cytometry
      • 6.1.2.1.8. Immunoassays
      • 6.1.2.1.9. Other In-vitro Diagnostic Testing Technologies
      • 6.1.2.2. Imaging
      • 6.1.2.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.2.2.2. Computed Tomography (CT)
      • 6.1.2.2.3. Positron Emission Tomography (PET)
      • 6.1.2.2.4. Mammography
      • 6.1.2.2.5. Ultrasound
      • 6.1.2.3. Biopsy Technologies
      • 6.1.2.4. Other
    • 6.1.3. By Cancer Type
      • 6.1.3.1. Breast Cancer
      • 6.1.3.2. Lung Cancer
      • 6.1.3.3. Colorectal Cancer
      • 6.1.3.4. Melanoma
      • 6.1.3.5. Blood Cancer
      • 6.1.3.6. Prostate Cancer
      • 6.1.3.7. Ovarian Cancer
      • 6.1.3.8. Stomach Cancer
      • 6.1.3.9. Liver Cancer
      • 6.1.3.10. Other Cancer
    • 6.1.4. By End-user
      • 6.1.4.1. Hospitals
      • 6.1.4.2. Diagnostic Laboratories
      • 6.1.4.3. Diagnostic Imaging Centers
      • 6.1.4.4. Cancer Research Institutes
      • 6.1.4.5. Others
    • 6.1.5. United States*
      • 6.1.5.1. By Product
      • 6.1.5.1.1. Consumables
      • 6.1.5.1.1.1. Antibodies
      • 6.1.5.1.1.2. Kits and Reagents
      • 6.1.5.1.1.3. Probes
      • 6.1.5.1.1.4. Other Consumables
      • 6.1.5.1.2. Instruments
      • 6.1.5.1.2.1. Pathology-based Instruments
      • 6.1.5.1.2.1.1. Slide Staining Systems
      • 6.1.5.1.2.1.2. Tissue Processing Systems
      • 6.1.5.1.2.1.3. Cell Processors
      • 6.1.5.1.2.1.4. PCR Instruments
      • 6.1.5.1.2.1.5. NGS Instruments
      • 6.1.5.1.2.1.6. Microarrays
      • 6.1.5.1.2.1.7. Other Pathology-based Instruments
      • 6.1.5.1.2.2. Imaging Instruments
      • 6.1.5.1.2.2.1. CT Instruments
      • 6.1.5.1.2.2.2. Ultrasound Instruments
      • 6.1.5.1.2.2.3. MRI Instruments
      • 6.1.5.1.2.2.4. PET Scan Instruments
      • 6.1.5.1.2.2.5. Mammography Instruments
      • 6.1.5.1.2.2.6. Other Nuclear Imaging Instruments
      • 6.1.5.1.2.3. Biopsy Instruments
      • 6.1.5.1.2.4. Other Instruments
      • 6.1.5.1.3. Services
      • 6.1.5.2. By Technology
      • 6.1.5.2.1. In-vitro Diagnostic Testing
      • 6.1.5.2.1.1. Polymerase Chain Reaction (PCR)
      • 6.1.5.2.1.2. Blood Test
      • 6.1.5.2.1.3. In-situ Hybridization (ISH)
      • 6.1.5.2.1.4. Immunohistochemistry
      • 6.1.5.2.1.5. Next-generation Sequencing (NGS)
      • 6.1.5.2.1.6. Microarrays
      • 6.1.5.2.1.7. Flow Cytometry
      • 6.1.5.2.1.8. Immunoassays
      • 6.1.5.2.1.9. Other In-vitro Diagnostic Testing Technologies
      • 6.1.5.2.2. Imaging
      • 6.1.5.2.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.5.2.2.2. Computed Tomography (CT)
      • 6.1.5.2.2.3. Positron Emission Tomography (PET)
      • 6.1.5.2.2.4. Mammography
      • 6.1.5.2.2.5. Ultrasound
      • 6.1.5.2.3. Biopsy Technologies
      • 6.1.5.2.4. Other
      • 6.1.5.3. By Cancer Type
      • 6.1.5.3.1. Breast Cancer
      • 6.1.5.3.2. Lung Cancer
      • 6.1.5.3.3. Colorectal Cancer
      • 6.1.5.3.4. Melanoma
      • 6.1.5.3.5. Blood Cancer
      • 6.1.5.3.6. Prostate Cancer
      • 6.1.5.3.7. Ovarian Cancer
      • 6.1.5.3.8. Stomach Cancer
      • 6.1.5.3.9. Liver Cancer
      • 6.1.5.3.10. Other Cancer
      • 6.1.5.4. By End-user
      • 6.1.5.4.1. Hospitals
      • 6.1.5.4.2. Diagnostic Laboratories
      • 6.1.5.4.3. Diagnostic Imaging Centers
      • 6.1.5.4.4. Cancer Research Institutes
      • 6.1.5.4.5. Others
    • 6.1.6. Canada
    • 6.1.7. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2022

  • 7.1. By Product
  • 7.2. By Technology
  • 7.3. By Cancer Type
  • 7.4. By End-user
  • 7.5. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Abbott
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Thermo Fisher Scientific Inc.
  • 14.3. Illumina, Inc.
  • 14.4. QIAGEN
  • 14.5. F. Hoffmann-La Roche Ltd
  • 14.6. Agilent Technologies, Inc.
  • 14.7. Quest Diagnostics Incorporated
  • 14.8. Merck KGaA
  • 14.9. Hologic, Inc.
  • 14.10. Becton, Dickinson and Company

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer